Breaking News Instant updates and real-time market news.

MRK

Merck

$54.90

-0.53 (-0.96%)

16:30
02/13/18
02/13
16:30
02/13/18
16:30

Merck discontinues APECS study

Merck announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1, in people with prodromal Alzheimer's disease. The decision to stop the study follows a recommendation by the external Data Monitoring Committee, which assessed overall benefit/risk during a recent interim safety analysis. The eDMC concluded that it was unlikely that positive benefit/risk could be established if the trial continued. Data from the APECS study will be presented at an upcoming medical meeting. "We are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "We are grateful to the patients and caregivers who participated in this study, and despite this outcome, Merck remains committed to developing novel therapies for the treatment of Alzheimer's and other neurodegenerative diseases."

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

MRK Merck
$54.90

-0.53 (-0.96%)

01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
01/16/18
RHCO
01/16/18
UPGRADE
RHCO
Buy
Merck upgraded to Buy from Hold at SunTrust
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.

TODAY'S FREE FLY STORIES

NRG

NRG Energy

$25.26

0.26 (1.04%)

05:49
02/23/18
02/23
05:49
02/23/18
05:49
Initiation
NRG Energy initiated  »

NRG Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

LDOS

Leidos

$65.75

0.54 (0.83%)

05:47
02/23/18
02/23
05:47
02/23/18
05:47
Recommendations
Leidos analyst commentary  »

Jefferies views Leidos as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTL

Entellus Medical

05:45
02/23/18
02/23
05:45
02/23/18
05:45
Conference/Events
Entellus Medical to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

FSLR

First Solar

$66.28

-0.42 (-0.63%)

05:44
02/23/18
02/23
05:44
02/23/18
05:44
Recommendations
First Solar analyst commentary  »

First Solar outlook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

HPP

Hudson Pacific

$30.66

0.42 (1.39%)

05:41
02/23/18
02/23
05:41
02/23/18
05:41
Upgrade
Hudson Pacific rating change  »

Hudson Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

05:40
02/23/18
02/23
05:40
02/23/18
05:40
Downgrade
Rosneft rating change  »

Rosneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$37.41

-26.21 (-41.20%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Macquarie Infrastructure rating change  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Acacia Communications rating change  »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 13

    Mar

  • 29

    Mar

XPO

XPO Logistics

$93.56

-0.43 (-0.46%)

05:37
02/23/18
02/23
05:37
02/23/18
05:37
Recommendations
XPO Logistics analyst commentary  »

XPO free cash flow growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$39.85

0.34 (0.86%)

, BIVV

Bioverativ

$104.30

0.39 (0.38%)

05:35
02/23/18
02/23
05:35
02/23/18
05:35
Hot Stocks
Sanofi announces expiration of HSR waiting period for acquisition of Bioverativ »

Sanofi (SNY) announced…

SNY

Sanofi

$39.85

0.34 (0.86%)

BIVV

Bioverativ

$104.30

0.39 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

KNX

Knight-Swift

$47.83

-0.47 (-0.97%)

05:34
02/23/18
02/23
05:34
02/23/18
05:34
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGL

Sibanye Gold

$4.05

-0.38 (-8.58%)

05:26
02/23/18
02/23
05:26
02/23/18
05:26
Upgrade
Sibanye Gold rating change  »

Sibanye Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGIF

Ingenico Group

05:23
02/23/18
02/23
05:23
02/23/18
05:23
Downgrade
Ingenico Group rating change  »

Ingenico Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$30.53

-1.44 (-4.50%)

05:22
02/23/18
02/23
05:22
02/23/18
05:22
Hot Stocks
Momo acquires Tantan in cash, stock transaction »

Momo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$55.43

-0.27 (-0.48%)

05:20
02/23/18
02/23
05:20
02/23/18
05:20
Recommendations
GoDaddy analyst commentary  »

GoDaddy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Mar

SRE

Sempra Energy

$106.64

1.21 (1.15%)

05:19
02/23/18
02/23
05:19
02/23/18
05:19
Hot Stocks
Sempra Energy raises annualized dividend by 9% to $3.58 per share »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

MB

Mindbody

$35.55

2.2 (6.60%)

05:18
02/23/18
02/23
05:18
02/23/18
05:18
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

05:17
02/23/18
02/23
05:17
02/23/18
05:17
Upgrade
Financial Engines rating change  »

Financial Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$35.82

0.49 (1.39%)

05:14
02/23/18
02/23
05:14
02/23/18
05:14
Initiation
Okta initiated  »

Okta initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 07

    Mar

COTV

Cotiviti Holdings

$34.21

-0.32 (-0.93%)

05:11
02/23/18
02/23
05:11
02/23/18
05:11
Downgrade
Cotiviti Holdings rating change  »

Cotiviti downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARD

Ardagh Group

$19.01

0.8 (4.39%)

05:09
02/23/18
02/23
05:09
02/23/18
05:09
Recommendations
Ardagh Group analyst commentary  »

Ardagh should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$26.48

-0.29 (-1.08%)

05:03
02/23/18
02/23
05:03
02/23/18
05:03
Initiation
Boston Scientific initiated  »

Boston Scientific assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

SGMO

Sangamo

$25.40

3.2 (14.41%)

, GILD

Gilead

$79.40

-1.29 (-1.60%)

05:00
02/23/18
02/23
05:00
02/23/18
05:00
Recommendations
Sangamo, Gilead analyst commentary  »

Sangamo price target…

SGMO

Sangamo

$25.40

3.2 (14.41%)

GILD

Gilead

$79.40

-1.29 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$101.51

0.42 (0.42%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Eastman Chemical management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

Week of 2/23 Baker-Hughes…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.